ANTIGEN LEVELS OF UROKINASE PLASMINOGEN-ACTIVATOR AND ITS RECEPTOR AT THE TUMOR-HOST INTERFACE OF COLORECTAL ADENOCARCINOMAS ARE RELATED TO TUMOR AGGRESSIVENESS

被引:60
作者
BUO, L
MELING, GI
KARLSRUD, TS
JOHANSEN, HT
AASEN, AO
机构
[1] UNIV OSLO,NATL HOSP,INST FORENS MED,N-0027 OSLO,NORWAY
[2] UNIV OSLO,INST PHARM,DEPT PHARMACOL,OSLO,NORWAY
关键词
COLORECTAL CANCER; UROKINASE PLASMINOGEN ACTIVATOR; IMMUNOHISTOCHEMISTRY;
D O I
10.1016/0046-8177(95)90276-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The distributions of urokinase and tissue plasminogen activators (uPA, tPA), uPA receptor (uPAR), and plasminogen activator inhibitors (PAI-1, PAI-2) were studied immunohistochemically in two subsets of colorectal adenocarcinomas with low and high aggressiveness, respectively: nine Dukes' stage A tumors with additional other good prognostic markers and 13 Dukes' stage C tumors with also other poor prognostic markers (referred to as Dukes' stage A and Dukes' stage C tumors). The results showed that these components of the tissue destructive plasminogen activation system were accumulated at the invading front of the tumors. Both tumor groups showed accumulations of uPA, uPAR, and PAI-1 at the tumor-host interface compared with the location within the tumor epithelium and the adjacent normal mucosa and muscularis propria (all P < .05). However, the uPA level at the tumor-host interface in the Dukes' stage C tumors was twice the level in the Dukes' stage A tumors (P < .05). The uPAR level was also significantly higher in the Dukes' stage C tumors (P < .05), whereas the PAI-1 level was not significantly higher. This may indicate that uPA in more aggressive tumors exceeds the inhibitory capacity represented by PAIs, resulting in enhanced tissue destructive potential that promotes tumor invasion. uPA and uPAR antigen levels and the uPA/PAI-1 ratio at the tumor-host interface appeared to be related to tumor aggressiveness in colorectal cancer. Copyright (C) 1995 by W.B. Saunders Company
引用
收藏
页码:1133 / 1138
页数:6
相关论文
共 44 条
  • [1] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - PROENZYME, RECEPTOR, AND INHIBITORS
    BLASI, F
    VASSALLI, JD
    DANO, K
    [J]. JOURNAL OF CELL BIOLOGY, 1987, 104 (04) : 801 - 804
  • [2] LOCATION OF PLASMINOGEN-ACTIVATOR (PA) AND PA INHIBITOR IN HUMAN COLORECTAL ADENOCARCINOMAS
    BUO, L
    LYBERG, T
    JORGENSEN, L
    JOHANSEN, HT
    AASEN, AO
    [J]. APMIS, 1993, 101 (03) : 235 - 241
  • [3] BUO L, 1994, ANTICANCER RES, V14, P2445
  • [4] CELL-MEMBRANE RECEPTORS FOR UROKINASE PLASMINOGEN-ACTIVATOR ARE INCREASED IN MALIGNANT OVARIAN-TUMORS
    CASSLEN, B
    GUSTAVSSON, B
    ASTEDT, B
    [J]. EUROPEAN JOURNAL OF CANCER, 1991, 27 (11) : 1445 - 1448
  • [5] CONOVER WJ, 1980, PRACTICAL NONPARAMET, P288
  • [6] IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES)
    CORDELL, JL
    FALINI, B
    ERBER, WN
    GHOSH, AK
    ABDULAZIZ, Z
    MACDONALD, S
    PULFORD, KAF
    STEIN, H
    MASON, DY
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) : 219 - 229
  • [7] PREVENTION OF METASTASIS BY INHIBITION OF THE UROKINASE RECEPTOR
    CROWLEY, CW
    COHEN, RL
    LUCAS, BK
    LIU, GH
    SHUMAN, MA
    LEVINSON, AD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) : 5021 - 5025
  • [8] RECEPTOR-MEDIATED INTERNALIZATION AND DEGRADATION OF UROKINASE IS CAUSED BY ITS SPECIFIC INHIBITOR PAI-1
    CUBELLIS, MV
    WUN, TC
    BLASI, F
    [J]. EMBO JOURNAL, 1990, 9 (04) : 1079 - 1085
  • [9] PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER
    DANO, K
    ANDREASEN, PA
    GRONDAHLHANSEN, J
    KRISTENSEN, P
    NIELSEN, LS
    SKRIVER, L
    [J]. ADVANCES IN CANCER RESEARCH, 1985, 44 : 139 - 266
  • [10] DEBRUIN PAF, 1987, CANCER RES, V47, P4654